Mesenchymal Cell Tissue Healing Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal tissue-derived cell therapies for tissue healing, such as those using mesenchymal stem cells and adipose tissue-derived multilineage progenitor cells, have limitations in enhancing tissue healing capabilities, particularly in chronic phase diseases like liver and cardiac tissue injuries.
Innovation Solution
Treatment of adherent cells derived from mesenchymal tissue, specifically adipose tissue-derived multilineage progenitor cells, with physiologically active polypeptides like interleukin-1 alpha (IL-1α) or interleukin-1 beta (IL-1β) to enhance their tissue healing potential, combined with a pharmaceutically acceptable carrier for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are used for tissue healing, then tissue protection and repair effects are achieved, but the healing ability is insufficient for chronic phase diseases
Solution Approach 1:
The patent applies parameter changes by treating mesenchymal stem cells with specific cytokines (IL-1α, IL-1β, TNF-α) to alter their functional state. This treatment modifies the cells' paracrine activity and secretory profile, enhancing their tissue healing capability without changing the cell type itself. The cytokine treatment transforms the cells from a baseline state to a hyper-active regenerative state, resolving the contradiction between reliability and productivity in chronic disease treatment.
Solution Approach 2:
The patent implements preliminary action by pre-treating mesenchymal stem cells with inflammatory cytokines before administration to the patient. This pre-conditioning step activates the cells' therapeutic potential in advance, ensuring they are optimally prepared to address chronic tissue injuries upon implantation. The preliminary cytokine exposure enhances the cells' secretory function and paracrine activity before they encounter the damaged tissue, thereby improving overall healing efficiency.
2Reliability
If cytokine treatment is applied to enhance cell function, then tissue healing ability is improved, but the complexity of the treatment process increases
Solution Approach 1:
The patent utilizes parameter changes by systematically varying cytokine concentration, treatment duration, and cell culture conditions to optimize the activation protocol. Through controlled experimentation, specific parameters (e.g., 10-100 ng/mL cytokine concentration for 24-72 hours) have been identified as optimal for enhancing therapeutic effect while maintaining process feasibility. This parameter optimization reduces unnecessary complexity by establishing standardized, reproducible treatment conditions.
Solution Approach 2:
The patent employs cytokines as intermediary substances that mediate between the administered cells and the damaged tissue. These cytokines (IL-1α, IL-1β, TNF-α) serve as signaling molecules that activate the mesenchymal stem cells, which then act as intermediaries to deliver therapeutic effects to the target tissue. This intermediary approach simplifies the overall treatment by using well-understood biological molecules to bridge the gap between cell administration and tissue repair.
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition containing: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptide or an LPS; and a pharmaceutically acceptable carrier.